Zacks Research Issues Pessimistic Estimate for IRWD Earnings

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Investment analysts at Zacks Research decreased their FY2026 earnings per share estimates for shares of Ironwood Pharmaceuticals in a report issued on Tuesday, December 10th. Zacks Research analyst R. Department now forecasts that the biotechnology company will post earnings per share of $0.43 for the year, down from their previous estimate of $0.44. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.08 per share.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.07). The firm had revenue of $91.60 million during the quarter, compared to analysts’ expectations of $91.22 million. Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. The company’s quarterly revenue was down 19.4% on a year-over-year basis. During the same quarter last year, the business posted $0.12 EPS.

A number of other brokerages also recently weighed in on IRWD. StockNews.com downgraded shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, November 12th. Leerink Partnrs raised shares of Ironwood Pharmaceuticals to a “hold” rating in a research report on Monday, September 9th. Finally, Leerink Partners began coverage on shares of Ironwood Pharmaceuticals in a report on Monday, September 9th. They issued a “market perform” rating and a $5.00 price target on the stock. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Ironwood Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $10.40.

Ironwood Pharmaceuticals Trading Down 0.8 %

IRWD stock opened at $3.53 on Friday. Ironwood Pharmaceuticals has a 1-year low of $3.06 and a 1-year high of $15.70. The stock has a market cap of $564.91 million, a P/E ratio of -117.67 and a beta of 0.41. The stock’s fifty day simple moving average is $4.01 and its two-hundred day simple moving average is $5.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. KBC Group NV raised its holdings in shares of Ironwood Pharmaceuticals by 59.3% during the 3rd quarter. KBC Group NV now owns 8,593 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 3,198 shares in the last quarter. CWM LLC raised its stake in shares of Ironwood Pharmaceuticals by 55.1% during the second quarter. CWM LLC now owns 6,600 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 2,345 shares during the last quarter. Wolverine Trading LLC purchased a new position in shares of Ironwood Pharmaceuticals during the third quarter valued at approximately $51,000. Diversified Trust Co purchased a new stake in Ironwood Pharmaceuticals in the third quarter worth $52,000. Finally, Legacy Capital Group California Inc. bought a new stake in shares of Ironwood Pharmaceuticals during the 3rd quarter valued at about $59,000.

Insider Activity at Ironwood Pharmaceuticals

In other news, CFO Sravan Kumar Emany sold 11,001 shares of the stock in a transaction on Monday, November 18th. The shares were sold at an average price of $4.08, for a total value of $44,884.08. Following the transaction, the chief financial officer now owns 309,572 shares of the company’s stock, valued at $1,263,053.76. This represents a 3.43 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 12.90% of the stock is owned by corporate insiders.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.